Indeed, in several human HCC cell lines, including SNU-182, Hep3B, and SNU-387, we observed that pre-treatment with recombinant IFNγ augmented sorafenib to inhibit the cell viability (Fig. 1a) and to enhance cell death (Fig. 1b). Here, IFNG is linked to hepatocellular carcinoma.